From: Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies
 | Hypertrophic scarring | Keloids |
---|---|---|
Incidence | 40% to 70% following surgery, up to 91% following burn injury Equal in sex distribution with highest incidence in the second to third decade | 6% to 16% In African populations |
Predilection sites | Shoulders, neck, presternum, knees and ankles Less affected: eyelids, cornea, palms, mucous membranes, genitalia and soles | Anterior chest, shoulders, earlobes, upper arms and cheeks |
Time course | Within 4 to 8 weeks following wounding, rapid growth phase for up to 6 months, then regression over a period of a few years Low recurrence rates after excision of the original hypertrophic scar | Within years after minor injuries or spontaneous formation on the midchest in the absence of any known injury. Persistence for long periods of time. No spontaneous regression High recurrence rates following excision |
Appearance | Do not extend beyond the initial site of injury | Projects beyond the original wound margins |
Histological characteristics | Primarily fine, well-organized, wavy type III collagen bundles oriented parallel to epidermis surface with abundant nodules containing myofibroblasts and plentiful acidic mucopolysaccharide. Proliferating cell nuclear antigen (PCNA)/p53-level/ATP expression low | Disorganized, large, thick, type I and III hypocellular collagen bundles with no nodules or excess myofibroblasts. Poor vascularization with widely scattered dilated blood vessels. PCNA/p53-level/ATP expression high |